GemPharmatech Co (SHSE:688046) ROCE % : 4.19% (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is GemPharmatech Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. GemPharmatech Co's annualized ROCE % for the quarter that ended in Sep. 2024 was 4.19%.

GemPharmatech Co ROCE % Historical Data

The historical data trend for GemPharmatech Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GemPharmatech Co ROCE % Chart

GemPharmatech Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

30.63

18.44

18.05

12.00

7.72

GemPharmatech Co Quarterly Data
	Dec18	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial														8.02	6.97	5.27	9.16	4.19

GemPharmatech Co ROCE % Calculation

GemPharmatech Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	164.049	/	( ( (2253.716 - 214.07)	+	(2577.59 - 366.409) )	/ 2 )
	=	164.049	/	( (2039.646	+	2211.181)	/ 2 )
	=	164.049	/	2125.4135
	=	7.72 %

GemPharmatech Co's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	91.672	/	( ( (2614.187 - 426.644)	+	(2533.54 - 341.385) )	/ 2 )
	=	91.672	/	( ( 2187.543	+	2192.155 )	/ 2 )
	=	91.672	/	2189.849
	=	4.19 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

GemPharmatech Co (SHSE:688046) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

GemPharmatech Co ROCE % Related Terms

Thank you for viewing the detailed overview of GemPharmatech Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

GemPharmatech Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GemPharmatech Co Ltd (SHSE:688046) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 12, Xuefu Road, Jiangbei New District, Jiangsu Province, Nanjing, CHN, 210032

Website

https://www.gempharmatech.us

GemPharmatech Co Ltd is a provider of?genetically engineered mouse?models?and services to global preclinical research and development communities. It specializes in developing animal models using cutting edge gene-editing technologies with a large collection of?cKO/KO (conditional knockout/knockout) mice, humanized mice, immunodeficient mice, and germ-free mice.

GemPharmatech Co Headlines

No Headlines